Skip to main content
MTSTinactive

METASTAT, INC.

Biopharma developer (SEC filing verified)·Commercial·Boston, MA, United States
Oncology

MTST evidence brief

What we can confirm

Market Cap:
$6K

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Market Cap: $6K
BioSniper AIPage evidence connected

Prepared research question

What matters most for MTST—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

Market Cap

$6K

Cash Runway

—

Lead Asset

—

Next Catalyst

—

Run METASTAT, INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available METASTAT, INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

Where is METASTAT, INC. headquartered?

METASTAT, INC. (MTST) is headquartered in Boston, MA, United States.

What therapeutic areas does METASTAT, INC. focus on?

METASTAT, INC. develops therapies across Oncology.

923 companies304,846 SEC filings22,720 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.